Skip to main content
. Author manuscript; available in PMC: 2017 Jul 31.
Published in final edited form as: Pharmacoepidemiol Drug Saf. 2016 Jan 22;25(4):363–371. doi: 10.1002/pds.3959

Table 3.

Calculation of the benefit-harm metric at 24 months follow-up

Outcome Number of outcomes if 1000
patients were treated
Number of outcomes
caused or prevented
by implant therapy

(NX = NX,SYS - NX,IMP)*
Weight assigned to
the outcome (WX)
NX * WX
Treated with
implant therapy
(NX,IMP)
Treated with
systemic therapy
(NX,SYS)
Visual acuity of the better-seeing eyes remained at worse than 20/40 or decreased to worse than 20/40 280 211 −69 0.8 −55
Incident glaucoma 226 60 −166 0.7 −116
Requiring cataract surgery 612 252 −359 0.6 −216
Requiring glaucoma surgery 331 67 −263 0.6 −158
Incident cataracts 173 86 −87 0.3 −26
Prescription-requiring hypertension 41 76 34 0.3 10
Prescription-requiring hyperlipidemia 25 67 42 0.3 13
Prescription-requiring infections 369 479 110 0.2 22

Benefit-harm metric (IX) 526
*

Numbers of outcomes caused are negative and numbers of outcomes prevented are positive.

Assuming 97% of patients at risk at baseline.

Assuming 18% of patients at risk at baseline.